Test IRB API push 4

Department
Primary Investigator
S
Stephen Bagley

Primary Investigator

Recruiting
99 years or below
All
Phase N/A

Brief description of study.

To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource
utilization.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 23 Jul 2026. Study ID: 20295550

Pre-Screener

Check your eligibility
Take up this questionnaire to help us determine if you have symptoms that are common to this clinical study. If you have the common symptoms, you may be eligible to take part in the study.-Default text

Preview complete

The prescreener preview is complete. You may now close the preview.

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team